Key result
Long-acting lipoglycopeptides show similar clinical success with cardiac device retention versus removal.
Why the study?
Long-acting lipoglycopeptides can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remained limited, particularly regarding surgical source control.
Does device retention compared to device removal affect clinical success in adults with orthopedic or cardiovascular device-associated infections treated with long-acting lipoglycopeptides?
Cohort (n=46)
Yes
Does device retention compared to device removal affect clinical success in adults with orthopedic or cardiovascular device-associated infections treated with long-acting lipoglycopeptides?
Long-acting lipoglycopeptide therapy in a day-hospital setting achieved an 87.0% clinical success rate in patients with orthopedic or cardiovascular device-associated infections, with similar outcomes observed between device retention and removal strategies.
Answers are grounded in this paper and cite their sources.
May support simplified therapy in select Gram-positive infections; hypothesis-generating and requires prospective validation.
Background: Long-acting lipoglycopeptides (LALs) can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remains limited, particularly in relation to surgical source control. Methods: We performed a post hoc secondary analysis of a previously published multicenter day-hospital cohort. Adults with orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection treated with at least one dose of dalbavancin and/or oritavancin between January 2020 and December 2025 were included; patients with an unrelated acute bacterial skin and skin-structure infection were excluded. Clinical outcomes were examined according to eventual device management (retention versus removal; total versus partial explantation). Results: Forty-six patients were included; median age was 72.3 years (IQR 60.4–79.1) and median Charlson Comorbidity Index was 4 (IQR 2.2–6.0). Prosthetic joint infection accounted for 25/46 cases (54.3%). Forty-five patients received a dalbavancin-containing regimen and 31/46 (67.4%) received LAL monotherapy. Clinical success at last available follow-up was 87.0% (40/46; exact 95% CI 73.7–95.1). Among the 40 patients with a classified source-control strategy and an infection involving the recorded device, success was 88.9% with retention (16/18) and 86.4% with removal (19/22); the exact conditional odds ratio was 1.26 (95% CI 0.13–16.79; Fisher p = 1.000). After removal, success was 89.5% after total explantation (17/19) and 66.7% after partial removal (2/3). C-reactive protein fell from 3.65 to 0.91 mg/dL (p < 0.001). Adverse drug events were mild and infrequent (2/40). Conclusions: In this post hoc, uncontrolled device-focused analysis, LAL-based day-hospital management was feasible with favorable observed outcomes. The source-control comparison was imprecise and cannot support superiority of retention or removal; it should be interpreted as descriptive and hypothesis-generating. Follow-up duration was not standardized, so durable cure could not be assessed.
No takes yet. Share an insight, caveat, or question.
Marıno et al. (2026) conducted a cohort in Orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection (n=46). Device retention with long-acting lipoglycopeptide therapy (dalbavancin and/or oritavancin) vs. Device removal with long-acting lipoglycopeptide therapy was evaluated on Clinical success at last available follow-up (OR 1.26, 95% CI 0.13-16.79, p=1.000). Long-acting lipoglycopeptide therapy achieved 87.0% clinical success overall, with similar rates between device retention and removal.
Synapse has enriched 10 related papers. Consider them for comparative context: